NCT00002101

Brief Summary

To compare the efficacy of clarithromycin/ethambutol with placebo or with rifabutin at two different doses in reducing colony-forming units (CFUs) by 2 or more logarithms in patients with Mycobacterium avium Complex bacteremia and maintaining this response until 16 weeks post-randomization. To assess survival and comparative tolerability among the three treatment regimens.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
450

participants targeted

Target at P50-P75 for phase_3

Geographic Reach
1 country

44 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 2, 1999

Completed
1.8 years until next milestone

First Posted

Study publicly available on registry

August 31, 2001

Completed
Last Updated

June 24, 2005

Status Verified

June 1, 1999

First QC Date

November 2, 1999

Last Update Submit

June 23, 2005

Conditions

Keywords

RifabutinMycobacterium avium-intracellulare InfectionDrug Therapy, CombinationEthambutolAcquired Immunodeficiency SyndromeClarithromycin

Interventions

Eligibility Criteria

Age13 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Concurrent Medication:
  • Allowed:
  • Isoniazid for TB prophylaxis ONLY.
  • Patients must have:
  • HIV infection.
  • MAC infection.
  • Life expectancy of at least 16 weeks.

You may not qualify if:

  • Co-existing Condition:
  • Patients with the following symptoms or conditions are excluded:
  • Perceived unreliability or unavailability for frequent monitoring.
  • Concurrent Medication:
  • Excluded:
  • Antimycobacterial drugs other than the study drugs.
  • Carbamazepine.
  • Terfenadine.
  • Theophylline.
  • Patients with the following prior condition are excluded:
  • History of hypersensitivity to rifabutin, rifampin, erythromycin, clarithromycin, azithromycin, or ethambutol.
  • Prior Medication:
  • Excluded within 7 days prior to study entry:
  • Rifabutin.
  • Rifampin.
  • +15 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (44)

McDowell Clinic

Phoenix, Arizona, 85006, United States

Location

Maricopa Med Research Foundation

Phoenix, Arizona, 85008, United States

Location

Bay Harbor Hosp

Harbor City, California, 90710, United States

Location

Ctr for Special Immunology

Irvine, California, 92718, United States

Location

Combat Group

Los Angeles, California, 90028, United States

Location

Cedars Sinai Med Ctr

Los Angeles, California, 90048, United States

Location

Highland Gen Hosp / San Francisco Gen Hosp

Oakland, California, 946021018, United States

Location

HIV Research Group

San Diego, California, 92102, United States

Location

UCSD / Ctr for Special Immunology

San Diego, California, 92103, United States

Location

Saint Francis Mem Hosp

San Francisco, California, 94109, United States

Location

San Francisco Veterans Administration Med Ctr

San Francisco, California, 94121, United States

Location

Sunnyvale Med Clinic

Sunnyvale, California, 94086, United States

Location

George Washington Univ Med Ctr

Washington D.C., District of Columbia, 20037, United States

Location

Veterans Administration Med Ctr

Washington D.C., District of Columbia, 20422, United States

Location

Infectious Disease Consultants

Altamonte Springs, Florida, 32701, United States

Location

TheraFirst Med Ctrs Inc

Fort Lauderdale, Florida, 33308, United States

Location

Dr Frank Tornaka

Fort Lauderdale, Florida, 33316, United States

Location

Gary Richmond MD

Fort Lauderdale, Florida, 33316, United States

Location

Dr Nelson Zide

Hollywood, Florida, 33021, United States

Location

Ctr for Special Immunology

Miami Beach, Florida, 33140, United States

Location

Dr Barry Rodwick

Safety Harbor, Florida, 34695, United States

Location

Bay Area AIDS Consortium

Tampa, Florida, 33609, United States

Location

Infectious Disease Research Consortium of Georgia

Atlanta, Georgia, 30345, United States

Location

Dr Daniel Berger

Chicago, Illinois, 60657, United States

Location

Univ of Kansas School of Medicine

Wichita, Kansas, 67214, United States

Location

Tulane Univ Med School

New Orleans, Louisiana, 701122699, United States

Location

Dr Arnold Markowitz

Keego Harbor, Michigan, 48320, United States

Location

Univ of Nebraska Med Ctr / HIV Clinic

Omaha, Nebraska, 681985130, United States

Location

East Orange Veterans Administration Med Ctr

East Orange, New Jersey, 07018, United States

Location

North Jersey Community Research Initiative

Newark, New Jersey, 071032842, United States

Location

Long Island Jewish Med Ctr

New Hyde Park, New York, 11042, United States

Location

Chelsea Village Med Ctr / Saint Vincent's Hosp

New York, New York, 10014, United States

Location

Community Health Network

Rochester, New York, 14620, United States

Location

Nalle Clinic

Charlotte, North Carolina, 28207, United States

Location

Polyclinic Med Ctr

Harrisburg, Pennsylvania, 17110, United States

Location

Buckley Braffman Stern Med Associates

Philadelphia, Pennsylvania, 19107, United States

Location

Charleston Veterans Administration Med Ctr

Charleston, South Carolina, 294015799, United States

Location

Dr Alfred F Burnside Jr

Columbia, South Carolina, 29204, United States

Location

Central Texas Med Foundation

Austin, Texas, 78751, United States

Location

Houston Veterans Administration Med Ctr

Houston, Texas, 77030, United States

Location

Univ TX San Antonio Health Science Ctr

San Antonio, Texas, 78284, United States

Location

Infectious Disease Physicians Inc

Annandale, Virginia, 22203, United States

Location

Univ of Wisconsin School of Medicine

Madison, Wisconsin, 53792, United States

Location

Milwaukee County Med Complex

Milwaukee, Wisconsin, 53226, United States

Location

MeSH Terms

Conditions

Mycobacterium avium-intracellulare InfectionHIV InfectionsAcquired Immunodeficiency Syndrome

Interventions

EthambutolClarithromycinRifabutin

Condition Hierarchy (Ancestors)

Mycobacterium Infections, NontuberculousMycobacterium InfectionsActinomycetales InfectionsGram-Positive Bacterial InfectionsBacterial InfectionsBacterial Infections and MycosesInfectionsBlood-Borne InfectionsCommunicable DiseasesSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System DiseasesSlow Virus Diseases

Intervention Hierarchy (Ancestors)

EthylenediaminesDiaminesPolyaminesAminesOrganic ChemicalsErythromycinMacrolidesPolyketidesLactonesRifamycinsHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsLactams, MacrocyclicMacrocyclic CompoundsPolycyclic Compounds

Study Design

Study Type
interventional
Phase
phase 3
Masking
DOUBLE
Purpose
TREATMENT
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

November 2, 1999

First Posted

August 31, 2001

Last Updated

June 24, 2005

Record last verified: 1999-06

Locations